About Immunitybio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://immunitybio.com/
Frequently Asked Questions
What is the 52-week range for IBRX?
The 52-week high is $12.43 and the 52-week low is $1.95.
What is the P/E ratio for IBRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for IBRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -193.29%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -598.56%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.09.
Analyst Recommendation Trends
Wall Street analyst consensus for IBRX over the last few months:
Latest IBRX News
ImmunityBio Stock Jumps: What's Going On?
ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.
IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger Bet
Vanguard’s six reporting entities collectively held 36.48 million shares after adding a net 2.43 million during Q2.
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months
ImmunityBio stock climbed over the $10 mark for the first time since March this year.
A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)
The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July, bringing its year-to-date performance to -10.0%. The fund attributed the decline to an unusual liquidity-driven dislocation across […]
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
ImmunityBio Inc. (NASDAQ:IBRX) saw its share price jump by 9.94 percent on Tuesday to finish at $9.29 apiece following a high-profile meeting between its founder, Dr. Patrick Soon-Shiong, and Turkish President Recep Tayyip Erdogan, fueling optimism around the listed firm’s planned expansion into Turkey. The Turkish government posted a photo of Erdogan and Soon-Shiong on […]
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?
Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.
IBRX Stock Eyes Worst Week Since July: New Patent Eyes Broader Anktiva Use Ahead Of Lung Cancer Conference
A new patent application covers using Anktiva to restore immune cells depleted by cancer treatments.
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.
Undercovered Dozen: Blue Owl Capital, Archer Aviation, Apollo Commercial And More
Discover Seeking Alphaâs Undercovered Dozenâ12 lesser-known stocks offering fresh investment ideas.
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ImmunityBio: None Of The Moonshots Is Priced In
ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.
Moderna: Massive Asymmetry About What The mRNA Is!
Moderna's upside hinges on Intismeranâs ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-02 | Cohen Cheryl | -55,979 | - | - |
| 2026-07-02 | Cohen Cheryl | -131,210 | $9.5034 | $1,246,941 |
| 2026-07-02 | Cohen Cheryl | +55,979 | $2.98 | $166,817 |
| 2026-07-01 | Selecky Christobel | -124,414 | - | - |
| 2026-07-01 | Selecky Christobel | -35,064 | - | - |
| 2026-07-01 | Selecky Christobel | -159,478 | $9.0236 | $1,439,066 |
| 2026-07-01 | Selecky Christobel | +124,414 | $2.99 | $371,998 |
| 2026-07-01 | Selecky Christobel | +35,064 | $2.98 | $104,491 |
| 2026-06-30 | Selecky Christobel | -300 | - | - |
| 2026-06-30 | Selecky Christobel | -700 | - | - |
| 2026-06-30 | Selecky Christobel | -1,000 | $9 | $9,000 |
| 2026-06-30 | Selecky Christobel | +300 | $2.99 | $897 |
| 2026-06-30 | Selecky Christobel | +700 | $2.98 | $2,086 |
| 2026-06-29 | Selecky Christobel | -30,000 | - | - |
| 2026-06-29 | Selecky Christobel | -33,549 | - | - |
| 2026-06-29 | Selecky Christobel | -32,173 | - | - |
| 2026-06-29 | Selecky Christobel | -95,722 | $9.0075 | $862,216 |
| 2026-06-29 | Selecky Christobel | +30,000 | $2.84 | $85,200 |
| 2026-06-29 | Selecky Christobel | +33,549 | $2.99 | $100,312 |
| 2026-06-29 | Selecky Christobel | +32,173 | $2.98 | $95,876 |
| 2026-06-24 | Simon Barry J. | -25,000 | $7.8763 | $196,908 |
| 2026-06-09 | Selecky Christobel | +65,600 | - | - |
| 2026-06-09 | MAXWELL LINDA | +65,600 | - | - |
| 2026-06-09 | Cohen Cheryl | +65,600 | - | - |
| 2026-06-09 | BLASZYK MICHAEL D | +65,600 | - | - |
| 2026-06-09 | Wendel Bruce | +65,600 | - | - |
| 2026-06-09 | Clark Wesley | +65,600 | - | - |
| 2026-06-04 | Simon Barry J. | -23,033 | $7.1769 | $165,306 |
| 2026-03-31 | SOON-SHIONG PATRICK | 0 | - | - |
| 2026-03-31 | SOON-SHIONG PATRICK | +4,606,596 | $5.427 | $24,999,996 |
| 2026-02-24 | Simon Barry J. | -75,000 | $12.0105 | $900,788 |
| 2026-02-23 | Selecky Christobel | -25,000 | - | - |
| 2026-02-23 | Selecky Christobel | -25,000 | $10 | $250,000 |
| 2026-02-23 | Selecky Christobel | +25,000 | $2.98 | $74,500 |
| 2026-02-23 | Simon Barry J. | -165,000 | $10.2491 | $1,691,102 |
| 2026-02-22 | Sachs David C. | -40,650 | - | - |
| 2026-02-22 | Sachs David C. | -20,682 | $8.7 | $179,933 |
| 2026-02-22 | Sachs David C. | +40,650 | - | - |
| 2026-02-22 | Adcock Richard | -152,439 | - | - |
| 2026-02-22 | Adcock Richard | -77,560 | $8.7 | $674,772 |
| 2026-02-22 | Adcock Richard | +152,439 | - | - |
| 2026-02-22 | Simon Barry J. | -15,243 | - | - |
| 2026-02-22 | Simon Barry J. | -6,026 | $8.7 | $52,426 |
| 2026-02-22 | Simon Barry J. | +15,243 | - | - |
| 2026-02-22 | LAUER REGAN J | -4,065 | - | - |
| 2026-02-22 | LAUER REGAN J | -1,673 | $8.7 | $14,555 |
| 2026-02-22 | LAUER REGAN J | +4,065 | - | - |
| 2026-02-22 | SOON-SHIONG PATRICK | -114,329 | - | - |
| 2026-02-22 | SOON-SHIONG PATRICK | -58,170 | $8.7 | $506,079 |
| 2026-02-22 | SOON-SHIONG PATRICK | +114,329 | - | - |
| 2026-02-20 | Simon Barry J. | -10,000 | $9.25 | $92,500 |
| 2026-02-10 | Sachs David C. | -82,236 | - | - |
| 2026-02-10 | Sachs David C. | -42,643 | $6.93 | $295,516 |
| 2026-02-10 | Sachs David C. | +82,236 | - | - |
| 2026-02-10 | Adcock Richard | -274,122 | - | - |
| 2026-02-10 | Adcock Richard | -140,048 | $6.93 | $970,533 |
| 2026-02-10 | Adcock Richard | +274,122 | - | - |
| 2026-02-10 | LAUER REGAN J | -5,482 | - | - |
| 2026-02-10 | LAUER REGAN J | -2,257 | $6.93 | $15,641 |
| 2026-02-10 | LAUER REGAN J | +5,482 | - | - |
| 2026-02-10 | SOON-SHIONG PATRICK | -274,122 | - | - |
| 2026-02-10 | SOON-SHIONG PATRICK | -118,560 | $6.93 | $821,621 |
| 2026-02-10 | SOON-SHIONG PATRICK | +274,122 | - | - |
| 2026-01-20 | Selecky Christobel | -25,000 | - | - |
| 2026-01-20 | Selecky Christobel | -25,000 | $7.506 | $187,650 |
| 2026-01-20 | Selecky Christobel | +25,000 | $2.98 | $74,500 |
| 2026-01-20 | Simon Barry J. | -75,000 | $7.8791 | $590,933 |
| 2026-01-20 | Simon Barry J. | -76,967 | $6.54 | $503,364 |
| 2026-01-16 | Selecky Christobel | -50,000 | - | - |
| 2026-01-16 | Selecky Christobel | -50,000 | $5 | $250,000 |
| 2026-01-16 | Selecky Christobel | +50,000 | $2.98 | $149,000 |
| 2025-12-31 | Sachs David C. | -30,397 | - | - |
| 2025-12-31 | Sachs David C. | -15,435 | $1.98 | $30,561 |
| 2025-12-31 | Sachs David C. | +30,397 | - | - |
| 2025-12-31 | Adcock Richard | -34,483 | - | - |
| 2025-12-31 | Adcock Richard | -17,510 | $1.98 | $34,670 |
| 2025-12-31 | Adcock Richard | +34,483 | - | - |
| 2025-12-12 | Wendel Bruce | +146,020 | - | - |